CD274 and neoplasm: Thus, considering the anti-tumor effect of ERK inhibitor and its regulatory role in tumor microenvironment, we reasoned that a combination treatment of ERK-targeted therapy and anti-PD-1/PD-L1 immunotherapy might block interactions between PD-1/PD-L1 pathway molecules more completely and restore CD8+T cell recognition in tumor cells to enhance the T cell-mediated immune response and anti-tumor activity.